Cencora expands 3PL and cold chain capabilities to enhance global pharmaceutical logistics
Key takeaways
- Cencora is expanding 3PL and cold chain capacity in the U.S. and Europe to support pharmaceutical logistics.
- New facilities include Italy (2026) and Texas (2028) for specialized storage and temperature-controlled products.
- Expanded logistics capabilities support complex pharmaceutical supply chains, including cell and gene therapies.
Cencora is enhancing its third-party logistics (3PL) capabilities in the U.S. and Europe, expanding its global network and strengthening specialty logistics services for pharmaceutical companies worldwide.
The company, which provides pharmaceutical solutions and logistics services, is increasing pan-European capabilities by adding NextPharma Logistics in Germany, Austria, and Switzerland, as well as opening a new 3PL facility in Italy in 2026.
In the U.S., Cencora will open a 500,000-square-foot 3PL facility in Texas in 2028 and has tripled ultra-low and cryogenic storage across its network.
“Pharmaceutical companies increasingly seek partners that can provide comprehensive support across multiple markets,” Alina Chesnokova, VP of global 3PL commercialization at Cencora, stated. “Through our internationally scaled 3PL service and suite of commercialization solutions, Cencora is uniquely positioned to support their needs, delivering integrated support to enable seamless expansion into new markets and ensure products are delivered on time and in the right condition.”
This piece was created with the assistance of generative AI tools and was edited by our content team for clarity and accuracy.